1. Home
  2. BX vs TOVX Comparison

BX vs TOVX Comparison

Compare BX & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Inc.

BX

Blackstone Inc.

N/A

Current Price

$115.91

Market Cap

94.1B

Sector

Finance

ML Signal

N/A

Logo Theriva Biologics Inc.

TOVX

Theriva Biologics Inc.

N/A

Current Price

$0.13

Market Cap

6.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BX
TOVX
Founded
1985
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.1B
6.4M
IPO Year
2007
2012

Fundamental Metrics

Financial Performance
Metric
BX
TOVX
Price
$115.91
$0.13
Analyst Decision
Buy
Buy
Analyst Count
25
2
Target Price
★ $139.04
$2.50
AVG Volume (30 Days)
★ 4.5M
1.1M
Earning Date
10-22-2026
11-12-2026
Dividend Yield
★ 4.09%
N/A
EPS Growth
6.91
★ 89.07
EPS
★ 3.19
N/A
Revenue
★ $14,450,265,000.00
N/A
Revenue This Year
$4.03
N/A
Revenue Next Year
$24.39
N/A
P/E Ratio
$36.37
★ N/A
Revenue Growth
★ 9.22
N/A
52 Week Low
$101.73
$0.13
52 Week High
$165.14
$0.49

Technical Indicators

Market Signals
Indicator
BX
TOVX
Relative Strength Index (RSI) 46.63 27.38
Support Level $105.57 N/A
Resistance Level $130.00 $0.25
Average True Range (ATR) 3.85 0.02
MACD -0.47 -0.00
Stochastic Oscillator 12.62 1.22

Price Performance

Historical Comparison
BX
TOVX

About BX Blackstone Inc.

Blackstone is the world's largest alternative-asset manager with $1.346 trillion in total assets under management, including $961.6 billion in fee-earning assets under management, at the end of June 2026. The company operates with scale in each of its major product lines: private equity (28% of fee-earning AUM and 35% of base management fees), real estate/real assets (29% and 32%), credit and insurance (33% and 25%), and other alternatives (10% and 8%). While the firm primarily serves institutional investors (84% of AUM), it also caters to clients in the high-net-worth channel (16%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

Share on Social Networks: